Drug-associated disease: Cytochrome P450 interactions

被引：33

作者：

Mann, HJ ^{[1
]}

机构：

[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA

来源：

CRITICAL CARE CLINICS | 2006年 / 22卷 / 02期

关键词：

D O I：

10.1016/j.ccc.2006.02.004

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Critically ill patients generally are older, frequently have organ failure, and commonly receive multiple medications, all of which make them susceptible to adverse effects of drugs. Drug interactions are a common adverse effect, and many are predictable based on understanding the mechanisms that underlie drug interactions. This article identifies commonly used medications in critically ill patients and the associated drug interactions that may occur with emphasis on the cytochrome P450 enzyme system.

引用

页码：329 / +

页数：18

共 64 条

[1]

Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582

[2] Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis [J].

Bastien, MC ;

Leblond, F ;

Pichette, V ;

Villeneuve, JP .

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2000, 78 (11) :912-919

[3] Clinically significant drug interactions with cholinesterase inhibitors -: A guide for neurologists [J].

Bentué-Ferrer, D ;

Tribut, O ;

Polard, E ;

Allain, H .

CNS DRUGS, 2003, 17 (13) :947-963

[4] The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective [J].

Bjornsson, TD ;

Callaghan, JT ;

Einolf, HJ ;

Fischer, V ;

Gan, L ;

Grimm, S ;

Kao, J ;

King, SP ;

Miwa, G ;

Ni, L ;

Kumar, G ;

McLeod, J ;

Obach, SR ;

Roberts, S ;

Roe, A ;

Shah, A ;

Snikeris, F ;

Sullivan, JT ;

Tweedie, D ;

Vega, JM ;

Walsh, J ;

Wrighton, SA .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) :443-469

[5]

BORCHARDTPHELPS PK, 1990, PERSPECTIVES CRITICA, V3, P108

[6] Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication [J].

Cascorbi, I .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 :17-22

[7] The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans [J].

Danielson, PB .

CURRENT DRUG METABOLISM, 2002, 3 (06) :561-597

[8] FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling [J].

Davit, B ;

Reynolds, K ;

Yuan, R ;

Ajayi, F ;

Conner, D ;

Fadiran, E ;

Gillespie, B ;

Sahajwalla, C ;

Huang, SM ;

Lesko, LJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (09) :899-910

[9] Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP4502C19 [J].

De Leon, J ;

Armstrong, SC ;

Cozza, KL .

PSYCHOSOMATICS, 2006, 47 (01) :75-85

[10] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

← 1 2 3 4 5 6 7 →